ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VLG Venture Life Group Plc

39.00
-0.50 (-1.27%)
22 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -1.27% 39.00 38.50 39.50 39.50 38.50 39.50 335,898 15:55:36
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Misc Retail Stores, Nec 43.98M 520k 0.0041 95.12 49.07M
Venture Life Group Plc is listed in the Misc Retail Stores sector of the London Stock Exchange with ticker VLG. The last closing price for Venture Life was 39.50p. Over the last year, Venture Life shares have traded in a share price range of 27.00p to 42.50p.

Venture Life currently has 125,831,530 shares in issue. The market capitalisation of Venture Life is £49.07 million. Venture Life has a price to earnings ratio (PE ratio) of 95.12.

Venture Life Share Discussion Threads

Showing 18726 to 18746 of 36725 messages
Chat Pages: Latest  761  760  759  758  757  756  755  754  753  752  751  750  Older
DateSubjectAuthorDiscuss
02/5/2018
13:10
Lauders

£400k 10 year convertible loan note @6.5% coupon.

Shareholders hung out to dry. The boffins can continue to have a jolly good time :-(


Cynical from Coventry.

red

redartbmud
02/5/2018
10:33
Brings me out in tiny, tiny spots, Lauders!

apad😊

apad
02/5/2018
10:29
Apad - The FARN BB has seen a marked increase in activity recently. Still not "that popular" yet ;-)

BVXP has been doing well recently. HCM too.

red - NANO news again. Apad had better not look. Grants, nano and graphene all mentioned in one RNS!

lauders
02/5/2018
10:11
Schroders backing Warpaint.

IQE LTIP!

Finished with FARN now. It's 3.2% of Stairway.
Only a few things to add to dacian's comment. There are no competitors. They will be producers. The drug mechanism is not limited to lungs.
Although not that widely researched, I have not seen such convincing Phase II results. Phase III trials seem to be conducted on borderline Phase II results.

apad😎

apad
02/5/2018
08:43
Hope so, homebrewruss, bought more this morning at 794.75.
Just following my big fierce animals principle.
Can't say I understand why the price is falling below the placing on the run up to results though.

Sorry, red, insensitive of me.

apad

apad
01/5/2018
22:43
APAD, this is partly why I was asking what your price expectations were for FARN a few days ago. It has already had a great run over the past year or so.

If you have a look at MTFB last year for example, it rose strongly after the trial completion and until the positive results were announced and has since fallen back and not done too much.

Hopefully you will prove us all wrong with your strategy however :)

homebrewruss
01/5/2018
22:30
I think FARN at current sp, has some degree of success built into the sp, so how much gain or loss you get based on good or bad results is impossible to predict. You should only allocate the money you can afford to lose to early stage pharma. When I bought more TUNE before the results, I was more sure that share price will rise after results than fall, but can I say the same about FARN, no
modform
01/5/2018
22:29
FARN .....The other issue is the outcome isn't down to the skill of the company - its down to what the compound does; and how the regulator interprets the data If it is safe and it does give benefit then fine; but however good the company the decision is based on the compounds performance. Risky in my book; especially for a large stake. I wish you well with it.
janeann
01/5/2018
21:42
It's a binary event - like 'investing' in a company drilling an oil well. Very different from investing in a quality sustainable business growing organically where value is not contingent on one single event. Re HP example I'm not keen on companies that make large (or in fact any) acquisitions as I've said here before. They add large risks where these didn't exist before the purchase. CLLN was just a poor quality business so not really relevant to this situation. You may well think you understand FARN and the odds are stacked in your favour. In fact I wouldn't bet against you. It's just not for me.
hydrus
01/5/2018
21:24
Hydrus, HP spent 7billion on Autonomy that they wrote off one year later.
Was that gambling?
Or was it an incorrect judgement?

I don't see my analysis of FARN as a 'gamble'.
Clearly a bad Phase III result is sudden death.
However, CLLN was just a slow death.

In some ways all investing is on a spectrum of risk.

Ney Ho.

apad

apad
01/5/2018
19:16
Thanks epo.

Sorted.

thelongandtheshortandthetall
01/5/2018
18:53
thelongandtheshortandthetall, type "google" into "the search this thread" box at the top of the page and look at the results.
epo001
01/5/2018
18:49
Just stumbled onto really healpful site www.dividenddata.co.uk

Worth a look gang.

thelongandtheshortandthetall
01/5/2018
17:43
Fun preentation:

www.piworld.co.uk/2018/05/01/adept-adt-presentation-at-mello-derby-2018/?ct=t(RSS_EMAIL_CAMPAIGN)

apad
01/5/2018
17:23
APAD you might feel the odds are good but it is gamble. They sort of have to get on and invest in manufacturing right? Don't think that's conclusive of anything. Any way good luck to those in it.
hydrus
01/5/2018
17:22
Dice are loaded, Hydrus.
apad😊

apad
01/5/2018
17:19
They have two manufacturing facilities and this was 29th Jan 2018, budsman.

"Faron’s wholly-owned product for Acute Respiratory Distress Syndrome on track for Phase III data in H1 2018
Faron Pharmaceuticals Ltd (“Faron”) (AIM: FARN), the clinical stage biopharmaceutical company, announces it has received Fast Track designation from the US Food and Drug Administration (FDA) for Traumakine®, the Company's wholly-owned product for the treatment of Acute Respiratory Distress Syndrome (ARDS). Traumakine is currently in two Phase III trials (INTEREST in Europe and MR11A8-2 in Japan), with top-line data from the INTEREST study on track for the first half of 2018.
Fast Track designation is granted by the FDA to expedite the review and facilitate the development of drugs to treat serious conditions with significant unmet medical need. The purpose of the process is to get new drugs to patients quicker. Today’s announced Fast Track designation is in addition to Traumakine’s Promising Innovative Medicines (PIM) designation from the MHRA, which is the first stage of the MHRA’s Early Access Medicines Scheme (EAMS).

apad
01/5/2018
17:18
Well, presumably those in FARN acknowledge it's just a straight gamble rather than a serious investment? Not my kind of thing. If I want to gamble I'll put a tenner on the horses rather than risk serious money.
hydrus
01/5/2018
17:04
Hopefully not bad news leaking out at FARN.

Bud

budsman
01/5/2018
17:04
Duplicate - apologies

Bud

budsman
01/5/2018
17:00
No longer showing this BOO short.
"JPMorgan Asset Management (UK) Short 0.50% 0.50% 16 Apr 2018"
From IGG:
"It’s a double whammy as they also scaled down their long position. It was the JPM UK Equity Growth fund that looks like the guys that de-risked.
BOO was their biggest recent decrease in position selling 77k shares @ 153p (ish) = 1.1m value of stock.
Market cap of BOO (at time of sale) = 1,757m
Sold mkt cap equiv = 0.06%"

My timing on FARN purchases is rubbish.
apad😡

apad
Chat Pages: Latest  761  760  759  758  757  756  755  754  753  752  751  750  Older

Your Recent History

Delayed Upgrade Clock